Paid to delay: The Tipline for 10 September 2021
Bausch Health has agreed to pay $300 million to settle claims it illegally prevented the launch of a rival diabetes drug. But it appears the pharmaceutical company still may come out on top. In the second half of 2015 alone, Bausch’s profits spiked by $350 million after it raised the wholesale cost of Glumetza from just over $5 to more than $50 a pill. Meanwhile, a division of the Department of Health and Human Services has proposed banning pay-for-delay agreements entirely.
Subscribe to Global Competition Review
Subscribe and start reading now
Global Competition Review (GCR) is the complete source of news and analysis for competition practitioners. It keeps you up to speed with the issues and trends that matter, giving you the detail, and depth, you need to operate successfully.
Already have access? Login below
Copyright © Law Business ResearchCompany Number: 03281866 VAT: GB 160 7529 10